Bovie Medical Provides J-PlasmaŽ Update

Wednesday, February 1, 2017 General News
Email Print This Page Comment bookmark
Font : A-A+

CLEARWATER, Fla., Jan. 31, 2017 /PRNewswire/ -- Bovie Medical Corporation (NYSE MKT: BVX), provided an update on its J-PlasmaŽ product.


Company disclosed that it is exploring new sales channel partnerships to further scale J-PlasmaŽ in the gynecology specialty.  The pilot program with Hologic that expires at the end of February 2017 will not be extended
as the two companies could not come to a mutually acceptable financial arrangement.

Additionally, the Company announced that:

  • Dr. Vipul Patel, a world-renowned urologist and leader in robotic surgery, is close to completing his clinical study of J-PlasmaŽ, with 90% of the designated patient population already enrolled.  Dr. Patel is examining the benefits of using J-PlasmaŽ for pelvic lymph node dissection. This procedure is frequently carried out to assess lymph node metastases following robotic prostatectomies and other oncological surgeries. The most common side effect of pelvic lymph node dissection is lymphocele formations, which can cause post-surgical complications requiring needle aspirations or other forms of drainage. Dr. Patel's study will determine whether more precise tools, such as J-PlasmaŽ, could significantly reduce the formation of lymphoceles.
  • Leading experts in plasma medicine at Old Dominion University published a study in the December, 2016 issue of Plasma Processes and Polymers in which cold plasma from Bovie's J-PlasmaŽ device was shown in a laboratory model to have the potential to kill a robust strain of prostate cancer cells and inhibit their proliferation. For details of the study please click this link:

The Company will release its fourth quarter and full year 2016 financial results after market on Thursday, March 9th and hold its analyst/investor conference call to discuss its financial performance and latest J-PlasmaŽ developments on Friday morning, March 10th.

About Bovie Medical Corporation

Bovie Medical Corporation is a leading maker of medical devices and supplies as well as the developer of J-PlasmaŽ, a patented new plasma-based surgical product for cutting and coagulation. J-PlasmaŽ utilizes a helium ionization process to produce a stable, focused beam of ionized gas that provides surgeons with greater precision, minimal invasiveness and an absence of conductive currents through the patient during surgery. Bovie Medical Corporation is also a leader in the manufacture of a range of electrosurgical products and technologies, marketed through both private labels and the Company's own well-respected brands (BovieŽ, AaronŽ, IDS™ and ICON™) to distributors worldwide. The Company also leverages its expertise through original equipment manufacturing (OEM) agreements with other medical device manufacturers. For further information about the Company's current and new products, please refer to the Investor Relations section of Bovie Medical Corporation's

To view the original version on PR Newswire, visit:

SOURCE Bovie Medical Corporation

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store